David C. Chang's Insider Trades & SAST Disclosures
David C. Chang's most recent trade in Allogene Therapeutics Inc was a trade of 46,668 Common Stock done at an average price of $2.0 . Disclosure was reported to the exchange on March 14, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern David C. Chang.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Allogene Therapeutics Inc | David D. Chang | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 1.96 per share. | 14 Mar 2025 | 46,668 | 5,276,569 (4%) | 0% | 2.0 | 91,469 | Common Stock |
| Cabaletta Bio Inc | David J. Chang | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 145,000 | 145,000 | - | - | Stock Option (Right to Buy) | |
| Allogene Therapeutics Inc | David D. Chang | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 1.68 per share. | 03 Feb 2025 | 46,003 | 5,317,237 (4%) | 0% | 1.7 | 77,285 | Common Stock |
| Allogene Therapeutics Inc | David D. Chang | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2025 | 1,952,130 | 1,952,130 | - | - | Stock Option (Right to buy) | |
| Allogene Therapeutics Inc | David D. Chang | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2025 | 552,174 | 5,363,240 (4%) | 0% | 0 | Common Stock | |
| Allogene Therapeutics Inc | David D. Chang | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 2.90 per share. | 16 May 2024 | 344,828 | 4,810,106 (3%) | 0% | 2.9 | 1,000,001 | Common Stock |
| AXT Inc | David C. Chang | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2024 | 23,323 | 252,572 (0%) | 0% | 0 | Common Stock | |
| Allogene Therapeutics Inc | David D. Chang | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.33 per share. | 14 Mar 2024 | 53,393 | 4,465,278 (3%) | 0% | 4.3 | 231,192 | Common Stock |
| Cabaletta Bio Inc | David J. Chang | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 130,000 | 130,000 | - | - | Stock Option (Right to Buy) | |
| Allogene Therapeutics Inc | Chang D. David | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2024 | 1,123,535 | 1,123,535 | - | - | Stock Option (Right to buy) | |
| Allogene Therapeutics Inc | D. David Chang | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2024 | 317,800 | 4,513,203 (3%) | 0% | 0 | Common Stock | |
| Allogene Therapeutics Inc | David D. Chang | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Mar 2023 | 1,924,464 | 4,193,911 (3%) | 1% | 0 | Common Stock | |
| Allogene Therapeutics Inc | David D. Chang | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Mar 2023 | 1,492,200 | 1,492,200 | - | - | Stock Option (Right to Buy) | |
| Allogene Therapeutics Inc | David D. Chang | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.56 per share. | 14 Mar 2023 | 22,340 | 2,269,447 (1%) | 0% | 5.6 | 124,210 | Common Stock |
| Cabaletta Bio Inc | David J. Chang | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2023 | 150,000 | 150,000 | - | - | Stock Option (Right to Buy) | |
| AXT Inc | David C. Chang | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2022 | 15,238 | 205,926 (0%) | 0% | 0 | Common Stock | |
| Allogene Therapeutics Inc | David D. Chang | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Mar 2022 | 2,195,512 | 2,195,512 | - | - | Stock Option (Right to Buy) | |
| Allogene Therapeutics Inc | David D. Chang | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 7.65 per share. | 15 Mar 2022 | 23,648 | 2,289,652 (1%) | 0% | 7.6 | 180,879 | Common Stock |
| Cabaletta Bio Inc | David J. Chang | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2022 | 135,000 | 135,000 | - | - | Stock Option (Right to Buy) | |
| Allogene Therapeutics Inc | David D. Chang | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 May 2021 | 27,410 | 541,190 | - | - | Stock Option (Right to Buy) | |
| Allogene Therapeutics Inc | David D. Chang | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.22 per share. | 24 May 2021 | 27,410 | 2,312,279 (1%) | 0% | 18.2 | 499,410 | Common Stock |
| AXT Inc | David C. Chang | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2021 | 6,726 | 190,688 (0%) | 0% | 0 | Common Stock | |
| Allogene Therapeutics Inc | David D. Chang | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 26 Mar 2021 | 205,778 | 856,044 (0%) | 0% | 0 | Common Stock | |
| Allogene Therapeutics Inc | David D. Chang | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 26 Mar 2021 | 205,778 | 856,044 (0%) | 0% | 0 | Common Stock | |
| Allogene Therapeutics Inc | David D. Chang | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 38.57 per share. | 15 Mar 2021 | 20,513 | 2,204,417 (1%) | 0% | 38.6 | 791,271 | Common Stock |
| Cabaletta Bio Inc | David J. Chang | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2021 | 113,500 | 113,500 | - | - | Stock Option (Right to Buy) | |
| AXT Inc | David C. Chang | Director | Sale of securities on an exchange or to another person at price $ 5.48 per share. | 28 May 2020 | 12,800 | 183,962 (0%) | 0% | 5.5 | 70,144 | Common Stock |
| AXT Inc | David C. Chang | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2020 | 10,909 | 196,762 (0%) | 0% | 0 | Common Stock | |
| Allogene Therapeutics Inc | David D. Chang | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 24 Apr 2020 | 428,022 | 650,266 (0%) | 0% | 0 | Common Stock | |
| Allogene Therapeutics Inc | David D. Chang | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 24 Apr 2020 | 428,022 | 650,266 (0%) | 0% | 0 | Common Stock | |
| Allogene Therapeutics Inc | David D. Chang | Director, President and CEO | Other type of transaction at price $ 0.00 per share. | 24 Apr 2020 | 9,198 | 1,201,108 (0%) | 0% | 0 | Common Stock | |
| Allogene Therapeutics Inc | David D. Chang | Director, President and CEO | Other type of transaction at price $ 0.00 per share. | 24 Apr 2020 | 9,187 | 2,224,101 (1%) | 0% | 0 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges